Literature DB >> 18191110

Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.

James L Reilly1, Margret S H Harris, Tin T Khine, Matcheri S Keshavan, John A Sweeney.   

Abstract

BACKGROUND: Problems with the voluntary control of behavior, such as those leading to increased antisaccade errors, are accepted as evidence of prefrontal dysfunction in schizophrenia. We previously reported that speeded prosaccade responses, i.e., shorter response latencies for automatic shifts of attention to visual targets, were associated with higher antisaccade error rates in schizophrenia. This suggests that dysregulation of automatic attentional processes may contribute to disturbances in prefrontally mediated control of voluntary behavior.
METHODS: Twenty-four antipsychotic-naïve schizophrenia patients and 30 healthy individuals completed three tasks: a no-gap prosaccade task in which subjects shifted gaze toward a peripheral target that appeared coincident with the disappearance of a central fixation target and separate prosaccade and antisaccade tasks in which a temporal gap or overlap of the central target offset and peripheral target onset occurred. Sixteen patients were retested after 6 weeks of antipsychotic treatment.
RESULTS: Patients' prosaccade latencies in the no-gap task were speeded compared with healthy individuals. While patients were not atypical in the degree to which response latencies were speeded or slowed by the gap and overlap manipulations, those patients with diminished attentional engagement on the prosaccade task (i.e., reduced overlap effect) had significantly elevated antisaccade error rates. This effect persisted in patients evaluated after antipsychotic treatment.
CONCLUSIONS: This study provides evidence that a reduced ability to engage attention may render patients more distracted by sensory inputs, thereby further compromising impaired executive control during antisaccade tasks. Thus, alterations in attentional and executive control functions can synergistically disrupt voluntary behavioral responses in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18191110      PMCID: PMC2366792          DOI: 10.1016/j.biopsych.2007.11.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  35 in total

Review 1.  Vying for dominance: dynamic interactions control visual fixation and saccadic initiation in the superior colliculus.

Authors:  Douglas P Munoz; Jillian H Fecteau
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

2.  Temporal stability of saccadic task performance in schizophrenia and bipolar patients.

Authors:  D C Gooding; L Mohapatra; H B Shea
Journal:  Psychol Med       Date:  2004-07       Impact factor: 7.723

Review 3.  The antisaccade task as a research tool in psychopathology: a critical review.

Authors:  Samuel B Hutton; Ulrich Ettinger
Journal:  Psychophysiology       Date:  2006-05       Impact factor: 4.016

Review 4.  fMRI studies of eye movement control: investigating the interaction of cognitive and sensorimotor brain systems.

Authors:  John A Sweeney; Beatriz Luna; Sarah K Keedy; Jennifer E McDowell; Brett A Clementz
Journal:  Neuroimage       Date:  2007-03-27       Impact factor: 6.556

5.  Reaction time of the Continuous Performance Test is an endophenotypic marker for schizophrenia: a study of first-episode neuroleptic-naive schizophrenia, their non-psychotic first-degree relatives and healthy population controls.

Authors:  Qiang Wang; Raymond Chan; Jinhua Sun; Jing Yao; Wei Deng; Xueli Sun; Xiehe Liu; Pak C Sham; Xiaohong Ma; Huaqing Meng; Robin M Murray; David A Collier; Tao Li
Journal:  Schizophr Res       Date:  2006-10-19       Impact factor: 4.939

6.  Intertrial effects of randomization on saccadic reaction times in human observers.

Authors:  H Weber; M Biscaldi; B Fischer
Journal:  Vision Res       Date:  1995-09       Impact factor: 1.886

7.  Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia.

Authors:  Margret S H Harris; James L Reilly; Matcheri S Keshavan; John A Sweeney
Journal:  Psychol Med       Date:  2006-01-03       Impact factor: 7.723

8.  Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects.

Authors:  Jennifer E McDowell; Gregory G Brown; Martin Paulus; Antigona Martinez; Sara E Stewart; David J Dubowitz; David L Braff
Journal:  Biol Psychiatry       Date:  2002-02-01       Impact factor: 13.382

9.  Smooth pursuit and saccadic abnormalities in first-episode schizophrenia.

Authors:  S B Hutton; T J Crawford; B K Puri; L J Duncan; M Chapman; C Kennard; T R Barnes; E M Joyce
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

10.  Saccadic system functioning among schizophrenia patients and their first-degree biological relatives.

Authors:  B A Clementz; J E McDowell; S Zisook
Journal:  J Abnorm Psychol       Date:  1994-05
View more
  27 in total

1.  Is the relationship of prosaccade reaction times and antisaccade errors mediated by working memory?

Authors:  Trevor J Crawford; Elisabeth Parker; Ivonne Solis-Trapala; Jenny Mayes
Journal:  Exp Brain Res       Date:  2010-11-25       Impact factor: 1.972

2.  Pre-cue fronto-occipital alpha phase and distributed cortical oscillations predict failures of cognitive control.

Authors:  Jordan P Hamm; Kara A Dyckman; Jennifer E McDowell; Brett A Clementz
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

3.  Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis.

Authors:  Toshikazu Ikuta; Delbert G Robinson; Juan A Gallego; Bart D Peters; Patricia Gruner; John Kane; Majnu John; Serge Sevy; Anil K Malhotra; Philip R Szeszko
Journal:  Psychiatry Res       Date:  2013-10-10       Impact factor: 3.222

4.  Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers.

Authors:  Brett A Clementz; John A Sweeney; Jordan P Hamm; Elena I Ivleva; Lauren E Ethridge; Godfrey D Pearlson; Matcheri S Keshavan; Carol A Tamminga
Journal:  Am J Psychiatry       Date:  2015-12-07       Impact factor: 18.112

5.  Sequential processing deficits in schizophrenia: relationship to neuropsychology and genetics.

Authors:  S Kristian Hill; Olivia Bjorkquist; Tarra Carrathers; Jarett E Roseberry; William C Hochberger; Jeffrey R Bishop
Journal:  Schizophr Res       Date:  2013-10-10       Impact factor: 4.939

6.  Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia.

Authors:  Sarah K Keedy; James L Reilly; Jeffrey R Bishop; Peter J Weiden; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-06-03       Impact factor: 9.306

Review 7.  The tell-tale tasks: a review of saccadic research in psychiatric patient populations.

Authors:  Diane C Gooding; Michele A Basso
Journal:  Brain Cogn       Date:  2008-10-23       Impact factor: 2.310

8.  Response suppression deficits in treatment-naïve first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression.

Authors:  Margret S H Harris; James L Reilly; Michael E Thase; Matcheri S Keshavan; John A Sweeney
Journal:  Psychiatry Res       Date:  2009-11-10       Impact factor: 3.222

9.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

Review 10.  Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery.

Authors:  James L Reilly; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-02-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.